- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07948070
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer
Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hao Jihui
- Número de teléfono: +86-02223340123
- Correo electrónico: haojihui@tjmuch.com
Ubicaciones de estudio
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana
- Reclutamiento
- Tianjin Medical University Cancer Institute & Hospital
-
Contacto:
- Hao Jihui, MD
- Número de teléfono: +86-02223340123
- Correo electrónico: haojihui@tjmuch.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Informed Consent Form (ICF) .
- Aged 18 to 70 years (inclusive) at the time of signing the ICF.
- Cytology or pathology confirmed Patients with pancreatic tumors.
Cohort 1:
- The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
- Adjuvant chemotherapy completed, as determined by the investigator.
Cohort 2:
- Disease progression after prior standard systemic antitumor therapy for the current disease stage;
- Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
- No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
- For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.
Cohort 3:
-
Patients receiving standard chemotherapy regimens include, but are not limited to:
- the oFOLFIRINOX regimen;
- gemcitabine combined with nab-paclitaxel; or
- other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
-
Patients receiving targeted therapy must meet all the following criteria:
- Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
- The investigator determines that no contraindications exist for the proposed targeted therapy.
-
ECOG score of 0 ~1 .
-
Expected survival time is more than 12 weeks.
-
Negative blood pregnancy test for females of childbearing potential is required.
Exclusion Criteria:
- Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
- History of bone marrow or organ transplantation;
- History of other primary malignancies;
- Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
- Patients with a known allergy to any component of the study drugs.
- History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
- Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
- Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
- Clinically significant thyroid dysfunction as assessed by the investigator.
- Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
- Clinically significant cardiovascular diseases.
- Insufficient bone marrow reserve or insufficient organ function.
- Female subjects who are pregnant or breastfeeding.
- Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
- The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohorte 1
|
Combination with Adjuvant Chemotherapy |
|
Experimental: Cohorte 2
|
GKPTZ-01 |
|
Experimental: Cohorte 3
|
Combination with Chemotherapy or Targeted Therapy |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrence-Free Survival
Periodo de tiempo: 2 years
|
6 months RFS(recurrence-free survival) rate(cohort 1) |
2 years
|
|
Objective response rate
Periodo de tiempo: 2 years
|
Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3) |
2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease Control Rate(DCR)
Periodo de tiempo: 2 years
|
Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01 |
2 years
|
|
Duration of Response(DOR)
Periodo de tiempo: 2 years
|
Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier |
2 years
|
|
Progression-free Survival(PFS)
Periodo de tiempo: 2 years
|
Time from GKPTZ-01 treatment to disease progression or death |
2 years
|
|
Overall survival(OS)
Periodo de tiempo: 2 years
|
Time from GKPTZ-01 treatment to death |
2 years
|
|
Adverse events
Periodo de tiempo: 2 years
|
The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events). |
2 years
|
|
Patient Quality of Life
Periodo de tiempo: 2 years
|
EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30) |
2 years
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pharmacokinetic
Periodo de tiempo: 2 years
|
Levels of T-cell Receptor copies |
2 years
|
|
Biomarker
Periodo de tiempo: 2 years
|
Concentration levels of serum cytokines, tumor markers |
2 years
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Terapéutica
- Terapia de modalidad combinada
- Terapia con drogas
- Quimioterapia, adyuvante
Otros números de identificación del estudio
- GATEWAY
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .